Critical Survey: Autonomix Medical (NASDAQ:AMIX) & Profound Medical (NASDAQ:PROF)

Autonomix Medical (NASDAQ:AMIX) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings for Autonomix Medical and Profound Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autonomix Medical	0	0	1	0	3.00
Profound Medical	0	0	2	1	3.33

Autonomix Medical currently has a consensus target price of $28.00, suggesting a potential upside of 952.63%. Profound Medical has a consensus target price of $14.25, suggesting a potential upside of 133.99%. Given Autonomix Medical’s higher probable upside, research analysts clearly believe Autonomix Medical is more favorable than Profound Medical.

Institutional & Insider Ownership

10.8% of Autonomix Medical shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 32.4% of Autonomix Medical shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Autonomix Medical and Profound Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autonomix Medical	N/A	-542.11%	-236.92%
Profound Medical	-349.41%	-85.22%	-64.87%

Earnings and Valuation

This table compares Autonomix Medical and Profound Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autonomix Medical	N/A	N/A	-$15.43 million	($16.07)	-0.17
Profound Medical	$7.20 million	25.41	-$28.57 million	($1.34)	-4.54

Autonomix Medical has higher earnings, but lower revenue than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Profound Medical beats Autonomix Medical on 8 of the 12 factors compared between the two stocks.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.